Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Two Novel Compounds With Tri-Aryl Structures As Effectivanti-Breast Cancer Candidates In-Vivo Publisher



Afsharinasab A1, 2 ; Moayer F3 ; Amini M4 ; Choopani S2 ; Tahmasvand R2 ; Dehghani S2 ; Mousavi SZ1 ; Salimi M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, (IAUPS), Tehran, Iran
  2. 2. Department of Physiology and pharmacology, Pasteur Institute of Iran, Tehran, Iran
  3. 3. Department of Pathobiology, College of Veterinary Medicine, Karaj Branch, Islamic Azad University, Alborz, Iran
  4. 4. Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Pharmaceutical Research Published:2020


Abstract

Prognosis of metastatic breast cancer is very poor which urges the necessity to develop novel potential drug candidates. We assessed two compounds with tri-aryl structures (A and B) for their potency to reduce primary breast tumor growth and lung metastasis in 4T1 mice model. MTT assay, 4T1 mammary mouse model, and immunohistochemistry experiments were used in this study. In-vitro results exhibited an anti–proliferative effect for compounds A and B towards MDA-MB-231 cancer cells. Our in-vivo results displayed that administered compounds A and B could suppress the size of the primary tumor and the number of lung metastatic foci in 4T1 BALB/c mice model. Histopathological analysis revealed that treatment of both compounds resulted in necrosis. Our findings provide new evidence that compound B may be promising for slowing the growth of tumor along with metastatic foci via COX-2 independent pathway. © 2020, Iranian Journal of Pharmaceutical Research. All rights reserved.
Other Related Docs